Novo launches online news channel for hemophilia patients; Sanofi's MS pill slows brain atrophy in Phase III;

> Novo Nordisk ($NVO) has launched an online news channel as part of its new website for hemophilia patients, More

> Sanofi's ($SNY) multiple sclerosis pill, Aubagio, slowed brain atrophy in a Phase III trial. Release

> The U.S. Department of Health and Human Services (HHS) is considering ideas to control drug prices, including contracting with drugmakers to pay based on performance. More (sub. req.)

> Formycon and Bioeq have launched a Phase III trial of their biosimilar of Roche's ($RHHBY) Lucentis. Report

And Finally... A guerrilla advertising campaign in Australia is encouraging gay men to have unprotected sex to promote Gilead's ($GILD) Truvada, which reduces the risk of contracting HIV. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.